Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study (Q33348171)

26 July 2017

title

Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study (English)

1 reference

malignant pleural mesothelioma

26 July 2017

main subject

1 reference

1 reference

Adolfo G Favaretto

1

0 references

Silvio Monfardini

object named as

Silvio Monfardini

11

0 references

author name string

Savina M L Aversa

2

1 reference

26 July 2017

Adriano Paccagnella

3

1 reference

26 July 2017

Vincenzo De Pangher Manzini

4

1 reference

26 July 2017

Valentina Palmisano

5

1 reference

26 July 2017

Francesco Oniga

6

1 reference

26 July 2017

Micaela Stefani

7

1 reference

26 July 2017

Federico Rea

8

1 reference

26 July 2017

Luigi Bortolotti

9

1 reference

26 July 2017

Lucio Loreggian

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

26 July 2017

1 reference

26 July 2017

volume

97

1 reference

26 July 2017

issue

11

1 reference

26 July 2017

page(s)

2791-2797

1 reference

Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Intracavitary bleomycin in the management of malignant effusions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Chemotherapy in malignant pleural mesothelioma. A review.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Phase II trial of carboplatin in the management of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11405

7 January 2021

Identifiers

DOI

10.1002/CNCR.11405

1 reference

26 July 2017

1 reference